Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Solution Marketing Manager at Elsevier
About the author:
Xuanyan joined Elsevier in October 2016 and currently works as a solution marketing manager. She holds a master’s degree in biochemistry and science-based business. Prior to Elsevier, she worked in QIAGEN and was involved in managing various parts of the life science portfolio. Xuanyan’s interests span several emerging fields, particularly pharmacovigilance and systematic review researches.
Posts by Xuanyan Xu
Posted on January 17th, 2019 in Pharma R&D
The partial shutdown of the U.S. government, which began just before the Christmas holiday, has been especially terrible for hundreds of thousands of federal employees who are either furloughed or working without pay. Continue reading “Government Shutdown Means New Drugs May Have to Wait – But Safety Monitoring Will Continue” »
Posted on January 15th, 2019 in Pharma R&D
In the pharmaceutical industry, safety protocols are rigorous. Clinical trials, a lengthy and intense part of the drug development process, are deemed absolutely crucial to ensuring the safety and efficacy of new drugs and therapies. There are also many regulations designed to make certain that high standards are maintained during the various trial phases.
Posted on February 9th, 2018 in Pharmacovigilance
A key component of any pharmacovigilance strategy is building search strings that successfully identify potential adverse events, which must be reported to regulatory agencies. If the query returns too narrow a result set, adverse events may be missed. Continue reading “In pharmacovigilance, effective search strings are key” »
Posted on August 30th, 2017 in Pharmacovigilance
Healthcare has been in the spotlight for much of the year so far, as Congress has wrestled with the difficult question of how to make it both better and more affordable.